- Merck (MRK +1.9%) submits its supplemental New Drug Application (sNDA) to the FDA seeking approval for the use of Keytruda (pembrolizumab) for the treatment of advanced non-small cell lung cancer whose disease has progressed on or after platinum-based chemo and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. The submission was based on data from the KEYNOTE-001 study.
- Keytruda is currently cleared for the treatment of melanoma.
Merck files for new indication for Keytruda
Recommended For You
More Trending News
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |